Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
1. ZYME reported a Q4 loss of 31 cents per share, missing expectations. 2. Sales of $31.03 million fell short of $45.2 million consensus. 3. ZYME prioritizes ZW251 for hepatocellular carcinoma, IND submission planned for 2025. 4. ZW220 Phase 1 studies paused despite encouraging preclinical data. 5. Ziihera received accelerated FDA approval for biliary tract cancer treatments.